However, the specificity and sensitivity of two traditional blood-based tumour biomarkers (CEA and CA19-9) have been evaluated to be low, especially for stratifying early stages of CRC [20, 21], which was further confirmed in our study. This evidence concerns the gene CEACAM5 and colorectal carcinoma.